Osteoporosis drugs “raloxifene” may prevent breast cancer

U.S. National Cancer Institute, a study shows that the U.S. company Eli Lilly osteoporosis treatment, “raloxifene” has the effect of the prevention of breast cancer may be breast cancer drug “tamoxifen” comparable, but the side effects of the former is smaller, therefore more secure.

According to local media reports, “raloxifene” and AstraZeneca’s “tamoxifen” in chemical composition are very similar.

U.S. researchers 19000 women to take these two kinds of drugs have been studied and found that postmenopausal women wear every day for 5 consecutive years, “raloxifene” and “tamoxifen” would make them suffer almost half of breast cancer risk reduction, while the postmenopausal women at high risk of breast cancer.

“Tamoxifen” for many years, older women suffering from breast cancer to prevent a drug, but there are reports that the drug has been found to induce uterine cancer and thrombosis. The U.S. National Cancer Institute believes that the “tamoxifen” than from “raloxifene” side-effects resulting from cases of uterine cancer and thrombosis, respectively 36% and 29% less.

Eli Lilly and Company said, will the U.S. Food and Drug Administration for approval, “raloxifene” At the same time as the sale of drugs to prevent breast cancer.